Poplar-type Propolis Dry Extract ESIT12 : Immunomodulation Efficacy Study
NCT05598749 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 309
Last updated 2024-09-25
Summary
The aim of the present investigation is to evaluate the immunomodulation effect of ESIT12, a poplar-type propolis dry extract standardized in polyphenols, and its efficacy in subjects at risk of contracting upper respiratory tract infections (URTIs), during a 12-week supplementation period plus 4-week follow-up.
The number of onset of upper respiratory tract infections, the symptoms severity and lasting and interferences with well-being will be assessed with WURSS-24 questionnaire. The quality of life will be assessed with the SF-36 questionnaire and a testimonial. Blood immune markers will also be assessed. Finally, long lasting benefits will additionally be evaluated 4 weeks after end of the supplementation period. The design of the study is double-blind, randomized, parallel and placebo controlled.
Conditions
- Upper Respiratory Tract Infection (URTI)
Interventions
- DIETARY_SUPPLEMENT
-
Placebo
Arabic gum, sucrose and silicon dioxide mix
- DIETARY_SUPPLEMENT
-
Verum
Propolis dry extract ESIT12 and carriers (arabic gum, sucrose and silicon dioxide mix)
Sponsors & Collaborators
-
Fytexia
lead INDUSTRY
Principal Investigators
-
Pedro Alcaraz · UCAM (Universidad Catolica San Antonio de Murcia)
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 25 Years
- Max Age
- 69 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-12-05
- Primary Completion
- 2024-07-03
- Completion
- 2024-07-03
Countries
- Spain
Study Locations
More Related Trials
-
Safety, Tolerability and Efficacy of S-1226 in Cystic Fibrosis and Non CF Bronchiectasis
NCT03903913 ·Status: UNKNOWN ·Phase: PHASE2
-
Live Vaccines and Innate Immune Training in COPD.
NCT06257212 ·Status: COMPLETED ·Phase: PHASE4
-
Clinical Evaluation of the AP203 Plant Extract Mixture in Adult Patients With Increased Incidence of Viral and/or Bacterial Upper Respiratory Tract Infections
NCT06020001 ·Status: COMPLETED ·Phase: NA
-
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen
NCT01644877 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Tolerability, and Clinical Activity of ASM-024 Administered to Patients With GOLD 2 or GOLD 3 Chronic Obstructive Pulmonary Disease (COPD)
NCT01855230 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy of EQ-778 on Upper Respiratory Tract Health Status in Healthy Adults
NCT05835375 ·Status: RECRUITING ·Phase: NA
-
Interferon-alpha Treatment of Chronic Cough in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis
NCT00690885 ·Status: TERMINATED ·Phase: PHASE2
-
Study to Reinforce Immunity (STRI) Phase 2 Clinical Trial
NCT05046561 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy and Safety of Tiotropium in Patients With COPD and Concomitant Diagnosis of Asthma
NCT00152984 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis
NCT06360094 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants
NCT06091579 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability and Efficacy Of S-1226 in Moderate Severity Covid-19 Bronchiolitis/Pneumonia
NCT04738136 ·Status: SUSPENDED ·Phase: PHASE2
-
Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia
NCT05531149 ·Status: TERMINATED ·Phase: PHASE3
-
Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)
NCT04317040 ·Status: COMPLETED ·Phase: PHASE3
-
The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2
NCT04313023 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
NCT05415137 ·Status: COMPLETED ·Phase: PHASE3
-
Inflammation in COPD and the Effect of Nicotinamide Riboside
NCT04990869 ·Status: COMPLETED ·Phase: NA
-
Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF)
NCT00639496 ·Status: COMPLETED ·Phase: PHASE3
-
Safety Study of Tetrathiomolybdate in Patients With Idiopathic Pulmonary Fibrosis
NCT00189176 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis
NCT00737100 ·Status: COMPLETED ·Phase: PHASE2
-
Lung Immune Challenge Study: Controlled Exposure to Inhaled Resiquimod (R848)
NCT06488118 ·Status: RECRUITING ·Phase: NA
-
LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT05321420 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Phase 1b Study of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT01254409 ·Status: COMPLETED ·Phase: PHASE1
-
A Study To Estimate The Time Course Of PF-00241939 Concentration In The Blood After Dosing With Oral Inhalation From Dry Powder Inhalers
NCT01181700 ·Status: COMPLETED ·Phase: PHASE1
-
Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis
NCT03218917 ·Status: COMPLETED ·Phase: PHASE2